{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T07:53:49Z","timestamp":1791273229817,"version":"4.1.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:00:00Z","timestamp":1791244800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:00:00Z","timestamp":1791244800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Respir Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Dupilumab reduced exacerbations in patients with COPD and type 2 inflammation in clinical trials; however, multicenter real-world data remain limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We performed a multicenter analysis of patients with COPD treated with dupilumab across centers in Germany. Patients with comorbid asthma were included to compare outcomes between COPD-only patients and those with comorbid asthma, as well as between patients with and without chronic bronchitis (CB). The primary endpoint was change in the annualized rate of moderate-to-severe exacerbations. Changes in lung function and CAT score were also assessed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 99 patients were included (60% male, mean age 66 years, FEV\u2081 37% predicted, DLCO 41% predicted, 45% comorbid asthma, 58% CB, 7% current smokers). Over a median follow-up of 11 months [IQR 8\u201314], dupilumab reduced the annualized moderate-to-severe exacerbation rate from 3.52 (95% CI 2.94\u20134.09) at baseline to 1.04 (95% CI 0.71\u20131.37) during follow-up, corresponding to a 70% reduction. Reductions in exacerbation rates were consistent irrespective of exacerbation severity, comorbid asthma, CB, or emphysema severity. CAT improved by a mean of 4.5 points. FEV\u2081 improved by 50 mL (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.077), while greater improvements were observed for residual volume (\u2212\u2009150 mL;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.071) and total airway resistance (\u2212\u200912.6%;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). Eight patients were non-responders and had no reduction in exacerbation under treatment.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In this real-world multicenter cohort, dupilumab effectively reduced exacerbation burden in patients with COPD and type 2 inflammation. Exploratory subgroup analyses suggested consistent treatment effects across different clinical phenotypes, although these findings require confirmation in larger studies. The high baseline exacerbation burden may partly explain the marked treatment response.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12931-026-03940-8","type":"journal-article","created":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T05:46:21Z","timestamp":1791265581000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world effectiveness of dupilumab in COPD: a German multicenter analysis"],"prefix":"10.1186","volume":"27","author":[{"given":"Mustafa","family":"Abdo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Skowasch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timm","family":"Greulich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nora","family":"Drick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marek","family":"Lommatzsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf-Harto","family":"H\u00fcbner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederik","family":"Trinkmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrin","family":"Milger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Rademacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantina","family":"Kontogianni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Aetou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Dreher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Alter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Pappe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonie","family":"Biener","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Sander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Heyckendorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathrin","family":"Kahnert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremias","family":"G\u00f6tschke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claus","family":"Neurohr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daiana","family":"Stolz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vera","family":"Veith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Watz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Waschki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pontus","family":"Mertsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,6]]},"reference":[{"issue":"8","key":"3940_CR1","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/S2213-2600(25)00215-2","volume":"13","author":"H Pott","year":"2025","unstructured":"Pott H, Sykes DL, Charriot J, Finney L, Yang F, Ramakrishnan S, et al. Breathing barriers: bridging lung health, research, and awareness. Lancet Respir Med. 2025;13(8):665\u20137.","journal-title":"Lancet Respir Med"},{"issue":"8","key":"3940_CR2","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/S2213-2600(24)00339-4","volume":"13","author":"MM de Oca","year":"2025","unstructured":"de Oca MM, Perez-Padilla R, Celli B, Aaron SD, Wehrmeister FC, Amaral AFS, et al. The global burden of COPD: epidemiology and effect of prevention strategies. Lancet Respir Med. 2025;13(8):709\u201324.","journal-title":"Lancet Respir Med"},{"key":"3940_CR3","unstructured":"Global strategy for the prevention, diagnosis and management of COPD: 2026 report."},{"issue":"2","key":"3940_CR4","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/S2213-2600(25)00362-5","volume":"14","author":"HWW Aung","year":"2026","unstructured":"Aung HWW, Vermeersch K, McAuley HJC, Ramakrishnan S, Abdo M, Beersaerts A, et al. Multidimensional prognostic risk stratification of COPD exacerbations: the baseline, acuity, and trigger (BAt) model. Lancet Respir Med. 2026;14(2):174\u201386.","journal-title":"Lancet Respir Med"},{"issue":"10","key":"3940_CR5","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1164\/rccm.202209-1748SO","volume":"208","author":"SP Bhatt","year":"2023","unstructured":"Bhatt SP, Agusti A, Bafadhel M, Christenson SA, Bon J, Donaldson GC, et al. Phenotypes, Etiotypes, and Endotypes of Exacerbations of Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2023;208(10):1026\u201341.","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"3940_CR6","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1164\/rccm.201104-0597OC","volume":"184","author":"M Bafadhel","year":"2011","unstructured":"Bafadhel M, McKenna S, Terry S, Mistry V, Reid C, Haldar P, et al. Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers. Am J Respir Crit Care Med. 2011;184(6):662\u201371.","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"3940_CR7","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1016\/j.jaci.2018.04.010","volume":"141","author":"JH Yun","year":"2018","unstructured":"Yun JH, Lamb A, Chase R, Singh D, Parker MM, Saferali A, et al. Blood eosinophil count thresholds and exacerbations in patients with chronic obstructive pulmonary disease. J Allergy Clin Immunol. 2018;141(6):2037\u2013e204710.","journal-title":"J Allergy Clin Immunol"},{"key":"3940_CR8","doi-asserted-by":"publisher","first-page":"108134","DOI":"10.1016\/j.rmed.2025.108134","volume":"243","author":"A Romero-Linares","year":"2025","unstructured":"Romero-Linares A, \u00c1lvarez-Muro L, Hammadi A, Hoyas-S\u00e1nchez C, Jim\u00e9nez-Ant\u00f3n A, Almansa-L\u00f3pez A, et al. Short term exacerbation risk and exhaled nitric oxide in COPD. Respir Med. 2025;243:108134.","journal-title":"Respir Med"},{"issue":"24","key":"3940_CR9","doi-asserted-by":"publisher","first-page":"2274","DOI":"10.1056\/NEJMoa2401304","volume":"390","author":"SP Bhatt","year":"2024","unstructured":"Bhatt SP, Rabe KF, Hanania NA, Vogelmeier CF, Bafadhel M, Christenson SA, et al. Dupilumab for COPD with Blood Eosinophil Evidence of Type 2 Inflammation. N Engl J Med. 2024;390(24):2274\u201383.","journal-title":"N Engl J Med"},{"issue":"3","key":"3940_CR10","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1056\/NEJMoa2303951","volume":"389","author":"SP Bhatt","year":"2023","unstructured":"Bhatt SP, Rabe KF, Hanania NA, Vogelmeier CF, Cole J, Bafadhel M, et al. Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts. N Engl J Med. 2023;389(3):205\u201314.","journal-title":"N Engl J Med"},{"key":"3940_CR11","doi-asserted-by":"crossref","unstructured":"Bhatt SP, Martinez FJ, Satia I, Anzueto A, Bourbeau J, Papi A, et al. Dupilumab in COPD: a pooled analysis of emergency department visits, hospital admissions, and systemic corticosteroid use. Am J Respir Crit Care Med. 2026;212(9):2011\u20132021.","DOI":"10.1093\/ajrccm\/aamag227"},{"key":"3940_CR12","doi-asserted-by":"crossref","unstructured":"Stanojevic S, Kaminsky DA, Miller MR, Thompson B, Aliverti A, Barjaktarevic I, et al. ERS\/ATS technical standard on interpretive strategies for routine lung function tests. Eur Respir J. 2022;60(1):2101499.","DOI":"10.1183\/13993003.01499-2021"},{"key":"3940_CR13","doi-asserted-by":"crossref","unstructured":"Bhakta NR, McGowan A, Ramsey KA, Borg B, Kivastik J, Knight SL, et al. European Respiratory Society\/American Thoracic Society technical statement: standardisation of the measurement of lung volumes, 2023 update. Eur Respir J. 2023;62(4):2201519.","DOI":"10.1183\/13993003.01519-2022"},{"issue":"3","key":"3940_CR14","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/S2213-2600(14)70001-3","volume":"2","author":"SSC Kon","year":"2014","unstructured":"Kon SSC, Canavan JL, Jones SE, Nolan CM, Clark AL, Dickson MJ, et al. Minimum clinically important difference for the COPD Assessment Test: a prospective analysis. Lancet Respir Med. 2014;2(3):195\u2013203.","journal-title":"Lancet Respir Med"},{"issue":"12","key":"3940_CR15","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1056\/NEJMoa0909883","volume":"363","author":"JR Hurst","year":"2010","unstructured":"Hurst JR, Vestbo J, Anzueto A, Locantore N, M\u00fcllerova H, Tal-Singer R, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010;363(12):1128\u201338.","journal-title":"N Engl J Med"},{"key":"3940_CR16","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.2147\/COPD.S525781","volume":"20","author":"O Freund","year":"2025","unstructured":"Freund O, Meoded O, Arnaout T, Friedman Regev I, Kupershmidt A, Enghelberg S, et al. Real-World Experience of Dupilumab Treatment for Patients with COPD - A Single Center Prospective Study. Int J Chron Obstruct Pulmon Dis. 2025;20:2753\u201360.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"3","key":"3940_CR17","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/S2213-2600(24)00409-0","volume":"13","author":"SP Bhatt","year":"2025","unstructured":"Bhatt SP, Rabe KF, Hanania NA, Vogelmeier CF, Bafadhel M, Christenson SA, et al. Dupilumab for chronic obstructive pulmonary disease with type 2 inflammation: a pooled analysis of two phase 3, randomised, double-blind, placebo-controlled trials. Lancet Respir Med. 2025;13(3):234\u201343.","journal-title":"Lancet Respir Med"},{"issue":"5","key":"3940_CR18","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1164\/rccm.202407-1379CI","volume":"211","author":"BR Celli","year":"2025","unstructured":"Celli BR, Christenson SA, Rabe KF, Han MK, van den Berge M, Criner GJ, et al. Current Smoker: A Clinical Chronic Obstructive Pulmonary Disease Phenotype Affecting Disease Progression and Response to Therapy. Am J Respir Crit Care Med. 2025;211(5):729\u201336.","journal-title":"Am J Respir Crit Care Med"},{"key":"3940_CR19","doi-asserted-by":"crossref","unstructured":"Abdo M, Pedersen F, Kirsten A-M, Trinkmann F, Groth EE, Bahmer T, et al. Association of airway inflammation and smoking status with IL-33 level in sputum of patients with asthma or COPD. Eur Respir J. 2024;64(3):2400347.","DOI":"10.1183\/13993003.00347-2024"},{"issue":"3","key":"3940_CR20","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1164\/rccm.201210-1843CI","volume":"187","author":"V Kim","year":"2013","unstructured":"Kim V, Criner GJ. Chronic bronchitis and chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2013;187(3):228\u201337.","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"3940_CR21","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1007\/s12016-025-09045-2","volume":"68","author":"L Sahnoon","year":"2025","unstructured":"Sahnoon L, Bajbouj K, Mahboub B, Hamoudi R, Hamid Q. Targeting IL-13 and IL-4 in Asthma: Therapeutic Implications on Airway Remodeling in Severe Asthma. Clin Rev Allergy Immunol. 2025;68(1):44.","journal-title":"Clin Rev Allergy Immunol"},{"key":"3940_CR22","doi-asserted-by":"publisher","first-page":"107846","DOI":"10.1016\/j.rmed.2024.107846","volume":"236","author":"SP Bhatt","year":"2025","unstructured":"Bhatt SP, Rabe KF, Hanania NA, Vogelmeier CF, Bafadhel M, Christenson SA, et al. Dupilumab reduces exacerbations and improves lung function in patients with chronic obstructive pulmonary disease and emphysema: Phase 3 randomized trial (BOREAS). Respir Med. 2025;236:107846.","journal-title":"Respir Med"},{"issue":"8","key":"3940_CR23","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/S2213-2600(25)00044-X","volume":"13","author":"SA Christenson","year":"2025","unstructured":"Christenson SA, Hanania NA, Bhatt SP, Bafadhel M, Rabe KF, Vogelmeier CF, et al. Type 2 inflammation biomarkers and their association with response to dupilumab in COPD (BOREAS): an analysis of a randomised, placebo-controlled, phase 3 trial. Lancet Respir Med. 2025;13(8):687\u201397.","journal-title":"Lancet Respir Med"},{"issue":"26","key":"3940_CR24","doi-asserted-by":"publisher","first-page":"2645","DOI":"10.1056\/NEJMoa032158","volume":"350","author":"JC Hogg","year":"2004","unstructured":"Hogg JC, Chu F, Utokaparch S, Woods R, Elliott WM, Buzatu L, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med. 2004;350(26):2645\u201353.","journal-title":"N Engl J Med"},{"key":"3940_CR25","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.2147\/COPD.S366911","volume":"17","author":"M Abdo","year":"2022","unstructured":"Abdo M, Pedersen F, Trinkmann F, Herth FJF, Rabe KF, Kirsten A-M, et al. Association of Airway Eosinophilia with Small Airway Dysfunction in Patients with Mild and at Risk for COPD. Int J Chron Obstruct Pulmon Dis. 2022;17:1403\u20138.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"3940_CR26","doi-asserted-by":"crossref","unstructured":"Maetani T, Tanabe N, Sato A, Shiraishi Y, Sakamoto R, Ogawa E, et al. Association between blood eosinophil count and small airway eosinophils in smokers with and without COPD. ERJ Open Res. 2023;9(5):00235\u20132023.","DOI":"10.1183\/23120541.00235-2023"}],"container-title":["Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12931-026-03940-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-026-03940-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-026-03940-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T07:30:44Z","timestamp":1791271844000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12931-026-03940-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,6]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3940"],"URL":"https:\/\/doi.org\/10.1186\/s12931-026-03940-8","relation":{},"ISSN":["1465-993X"],"issn-type":[{"value":"1465-993X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,6]]},"assertion":[{"value":"24 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the ethics committee at the University of L\u00fcbeck School of Medicine (L\u00fcbeck, Germany; Az. 2026-085).","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The requirement for informed consent was waived by the responsible ethics committee because this retrospective study was based on electronic medical records and met the criteria for a waiver of informed consent under applicable regulations.","order":2,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors meet criteria for authorship as recommended by the International Committee of Medical Journal Editors (ICMJE).","order":4,"name":"Ethics","label":"Disclosure","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"During the preparation of this work the author(s) used ChatGPT in order to check for writing, grammar, and formulation of language. After using this tool\/service, the author(s) reviewed and edited the content as needed and take(s) full responsibility for the content of the published article.","order":5,"name":"Ethics","label":"Generative AI and AI-assisted technologies in the manuscript preparation process","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":6,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"386"}}